Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Safety and Efficacy Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

NCT06682806 is registered in ClinicalTrials.gov with Prelude Therapeutics as lead sponsor.

NCT NCT06682806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06682806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Safety and Efficacy Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Lead sponsor
Prelude Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
June 3, 2025
Completion date
January 23, 2026
Enrollment
6 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, esophageal cancer, metastatic solid tumor, non-small cell lung cancers, smarca4 gene mutation